The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drugs for NSCLC Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Targeted Drugs for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Targeted Drugs for NSCLC market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Squamous Cell Carcinoma of NSCLC accounting for % of the Targeted Drugs for NSCLC global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Target EGFR segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Targeted Drugs for NSCLC include Allergan, Amgen, ARIAD Pharmaceuticals (Takeda), Beacon Pharma Limited, and BeiGene, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Targeted Drugs for NSCLC market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems (Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca
Cipla
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Natco Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Targeted Drugs for NSCLC product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Targeted Drugs for NSCLC, with revenue, gross margin and global market share of Targeted Drugs for NSCLC from 2019 to 2022.
Chapter 3, the Targeted Drugs for NSCLC competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Targeted Drugs for NSCLC market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Targeted Drugs for NSCLC research findings and conclusion, appendix and data source.
Geographical Area
Global
The Targeted Drugs for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Targeted Drugs for NSCLC market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Squamous Cell Carcinoma of NSCLC accounting for % of the Targeted Drugs for NSCLC global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Target EGFR segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Targeted Drugs for NSCLC include Allergan, Amgen, ARIAD Pharmaceuticals (Takeda), Beacon Pharma Limited, and BeiGene, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Targeted Drugs for NSCLC market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems (Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca
Cipla
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Natco Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Targeted Drugs for NSCLC product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Targeted Drugs for NSCLC, with revenue, gross margin and global market share of Targeted Drugs for NSCLC from 2019 to 2022.
Chapter 3, the Targeted Drugs for NSCLC competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Targeted Drugs for NSCLC market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Targeted Drugs for NSCLC research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Targeted Drugs for NSCLC
1.2 Classification of Targeted Drugs for NSCLC by Type
1.2.1 Overview: Global Targeted Drugs for NSCLC Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Targeted Drugs for NSCLC Revenue Market Share by Type in 2021
1.2.3 Target EGFR
1.2.4 Target ALK
1.2.5 Target HER2
1.2.6 Target ROS1
1.2.7 Target BRAF
1.2.8 Target MEK
1.2.9 Target VEGFR2
1.2.10 Target VEGF
1.2.11 Target MET
1.3 Global Targeted Drugs for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drugs for NSCLC Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drugs for NSCLC Market Size & Forecast
1.5 Global Targeted Drugs for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drugs for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Targeted Drugs for NSCLC Market Size by Region, (2017-2022)
1.5.3 North America Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)
1.5.4 Europe Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)
1.5.6 South America Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drugs for NSCLC Market Drivers
1.6.2 Targeted Drugs for NSCLC Market Restraints
1.6.3 Targeted Drugs for NSCLC Trends Analysis
2 Company Profiles
2.1 Allergan
2.1.1 Allergan Details
2.1.2 Allergan Major Business
2.1.3 Allergan Targeted Drugs for NSCLC Product and Solutions
2.1.4 Allergan Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Allergan Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Targeted Drugs for NSCLC Product and Solutions
2.2.4 Amgen Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Amgen Recent Developments and Future Plans
2.3 ARIAD Pharmaceuticals (Takeda)
2.3.1 ARIAD Pharmaceuticals (Takeda) Details
2.3.2 ARIAD Pharmaceuticals (Takeda) Major Business
2.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product and Solutions
2.3.4 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans
2.4 Beacon Pharma Limited
2.4.1 Beacon Pharma Limited Details
2.4.2 Beacon Pharma Limited Major Business
2.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Product and Solutions
2.4.4 Beacon Pharma Limited Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Beacon Pharma Limited Recent Developments and Future Plans
2.5 BeiGene
2.5.1 BeiGene Details
2.5.2 BeiGene Major Business
2.5.3 BeiGene Targeted Drugs for NSCLC Product and Solutions
2.5.4 BeiGene Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 BeiGene Recent Developments and Future Plans
2.6 Biocon
2.6.1 Biocon Details
2.6.2 Biocon Major Business
2.6.3 Biocon Targeted Drugs for NSCLC Product and Solutions
2.6.4 Biocon Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Biocon Recent Developments and Future Plans
2.7 Boehringer-Ingelheim
2.7.1 Boehringer-Ingelheim Details
2.7.2 Boehringer-Ingelheim Major Business
2.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Product and Solutions
2.7.4 Boehringer-Ingelheim Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Boehringer-Ingelheim Recent Developments and Future Plans
2.8 Celgene Corporation
2.8.1 Celgene Corporation Details
2.8.2 Celgene Corporation Major Business
2.8.3 Celgene Corporation Targeted Drugs for NSCLC Product and Solutions
2.8.4 Celgene Corporation Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Celgene Corporation Recent Developments and Future Plans
2.9 Drug International Limted
2.9.1 Drug International Limted Details
2.9.2 Drug International Limted Major Business
2.9.3 Drug International Limted Targeted Drugs for NSCLC Product and Solutions
2.9.4 Drug International Limted Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Drug International Limted Recent Developments and Future Plans
2.10 Fujifilm Kyowa Kirin Biologics
2.10.1 Fujifilm Kyowa Kirin Biologics Details
2.10.2 Fujifilm Kyowa Kirin Biologics Major Business
2.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product and Solutions
2.10.4 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Fujifilm Kyowa Kirin Biologics Recent Developments and Future Plans
2.11 Genvio Pharma Limited
2.11.1 Genvio Pharma Limited Details
2.11.2 Genvio Pharma Limited Major Business
2.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Product and Solutions
2.11.4 Genvio Pharma Limited Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Genvio Pharma Limited Recent Developments and Future Plans
2.12 Hetero Drugs
2.12.1 Hetero Drugs Details
2.12.2 Hetero Drugs Major Business
2.12.3 Hetero Drugs Targeted Drugs for NSCLC Product and Solutions
2.12.4 Hetero Drugs Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Hetero Drugs Recent Developments and Future Plans
2.13 ImClone Systems (Eli Lilly)
2.13.1 ImClone Systems (Eli Lilly) Details
2.13.2 ImClone Systems (Eli Lilly) Major Business
2.13.3 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product and Solutions
2.13.4 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 ImClone Systems (Eli Lilly) Recent Developments and Future Plans
2.14 Incepta Pharmaceuticals
2.14.1 Incepta Pharmaceuticals Details
2.14.2 Incepta Pharmaceuticals Major Business
2.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions
2.14.4 Incepta Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Incepta Pharmaceuticals Recent Developments and Future Plans
2.15 Mylan
2.15.1 Mylan Details
2.15.2 Mylan Major Business
2.15.3 Mylan Targeted Drugs for NSCLC Product and Solutions
2.15.4 Mylan Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Mylan Recent Developments and Future Plans
2.16 Novartis
2.16.1 Novartis Details
2.16.2 Novartis Major Business
2.16.3 Novartis Targeted Drugs for NSCLC Product and Solutions
2.16.4 Novartis Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Novartis Recent Developments and Future Plans
2.17 Pfizer
2.17.1 Pfizer Details
2.17.2 Pfizer Major Business
2.17.3 Pfizer Targeted Drugs for NSCLC Product and Solutions
2.17.4 Pfizer Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Pfizer Recent Developments and Future Plans
2.18 Reliance Lifesciences
2.18.1 Reliance Lifesciences Details
2.18.2 Reliance Lifesciences Major Business
2.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Product and Solutions
2.18.4 Reliance Lifesciences Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Reliance Lifesciences Recent Developments and Future Plans
2.19 Roche
2.19.1 Roche Details
2.19.2 Roche Major Business
2.19.3 Roche Targeted Drugs for NSCLC Product and Solutions
2.19.4 Roche Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Roche Recent Developments and Future Plans
2.20 AstraZeneca
2.20.1 AstraZeneca Details
2.20.2 AstraZeneca Major Business
2.20.3 AstraZeneca Targeted Drugs for NSCLC Product and Solutions
2.20.4 AstraZeneca Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 AstraZeneca Recent Developments and Future Plans
2.21 Cipla
2.21.1 Cipla Details
2.21.2 Cipla Major Business
2.21.3 Cipla Targeted Drugs for NSCLC Product and Solutions
2.21.4 Cipla Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Cipla Recent Developments and Future Plans
2.22 Teva
2.22.1 Teva Details
2.22.2 Teva Major Business
2.22.3 Teva Targeted Drugs for NSCLC Product and Solutions
2.22.4 Teva Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Teva Recent Developments and Future Plans
2.23 OSI Pharmaceuticals
2.23.1 OSI Pharmaceuticals Details
2.23.2 OSI Pharmaceuticals Major Business
2.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions
2.23.4 OSI Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 OSI Pharmaceuticals Recent Developments and Future Plans
2.24 Glenmark Pharmaceuticals
2.24.1 Glenmark Pharmaceuticals Details
2.24.2 Glenmark Pharmaceuticals Major Business
2.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions
2.24.4 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.24.5 Glenmark Pharmaceuticals Recent Developments and Future Plans
2.25 Natco Pharma
2.25.1 Natco Pharma Details
2.25.2 Natco Pharma Major Business
2.25.3 Natco Pharma Targeted Drugs for NSCLC Product and Solutions
2.25.4 Natco Pharma Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.25.5 Natco Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drugs for NSCLC Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drugs for NSCLC Players Market Share in 2021
3.2.2 Top 10 Targeted Drugs for NSCLC Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Targeted Drugs for NSCLC Players Head Office, Products and Services Provided
3.4 Targeted Drugs for NSCLC Mergers & Acquisitions
3.5 Targeted Drugs for NSCLC New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drugs for NSCLC Revenue and Market Share by Type (2017-2022)
4.2 Global Targeted Drugs for NSCLC Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Targeted Drugs for NSCLC Revenue Market Share by Application (2017-2022)
5.2 Global Targeted Drugs for NSCLC Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drugs for NSCLC Revenue by Type (2017-2028)
6.2 North America Targeted Drugs for NSCLC Revenue by Application (2017-2028)
6.3 North America Targeted Drugs for NSCLC Market Size by Country
6.3.1 North America Targeted Drugs for NSCLC Revenue by Country (2017-2028)
6.3.2 United States Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
6.3.3 Canada Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
6.3.4 Mexico Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drugs for NSCLC Revenue by Type (2017-2028)
7.2 Europe Targeted Drugs for NSCLC Revenue by Application (2017-2028)
7.3 Europe Targeted Drugs for NSCLC Market Size by Country
7.3.1 Europe Targeted Drugs for NSCLC Revenue by Country (2017-2028)
7.3.2 Germany Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
7.3.3 France Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
7.3.5 Russia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
7.3.6 Italy Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drugs for NSCLC Revenue by Type (2017-2028)
8.2 Asia-Pacific Targeted Drugs for NSCLC Revenue by Application (2017-2028)
8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drugs for NSCLC Revenue by Region (2017-2028)
8.3.2 China Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
8.3.3 Japan Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
8.3.4 South Korea Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
8.3.5 India Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
8.3.7 Australia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drugs for NSCLC Revenue by Type (2017-2028)
9.2 South America Targeted Drugs for NSCLC Revenue by Application (2017-2028)
9.3 South America Targeted Drugs for NSCLC Market Size by Country
9.3.1 South America Targeted Drugs for NSCLC Revenue by Country (2017-2028)
9.3.2 Brazil Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
9.3.3 Argentina Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drugs for NSCLC Revenue by Type (2017-2028)
10.2 Middle East & Africa Targeted Drugs for NSCLC Revenue by Application (2017-2028)
10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drugs for NSCLC Revenue by Country (2017-2028)
10.3.2 Turkey Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
10.3.4 UAE Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Targeted Drugs for NSCLC Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Targeted Drugs for NSCLC Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Targeted Drugs for NSCLC Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Targeted Drugs for NSCLC Revenue (USD Million) by Region (2017-2022)
Table 5. Global Targeted Drugs for NSCLC Revenue Market Share by Region (2023-2028)
Table 6. Allergan Corporate Information, Head Office, and Major Competitors
Table 7. Allergan Major Business
Table 8. Allergan Targeted Drugs for NSCLC Product and Solutions
Table 9. Allergan Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Amgen Corporate Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Targeted Drugs for NSCLC Product and Solutions
Table 13. Amgen Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. ARIAD Pharmaceuticals (Takeda) Corporate Information, Head Office, and Major Competitors
Table 15. ARIAD Pharmaceuticals (Takeda) Major Business
Table 16. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product and Solutions
Table 17. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Beacon Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 19. Beacon Pharma Limited Major Business
Table 20. Beacon Pharma Limited Targeted Drugs for NSCLC Product and Solutions
Table 21. Beacon Pharma Limited Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. BeiGene Corporate Information, Head Office, and Major Competitors
Table 23. BeiGene Major Business
Table 24. BeiGene Targeted Drugs for NSCLC Product and Solutions
Table 25. BeiGene Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Biocon Corporate Information, Head Office, and Major Competitors
Table 27. Biocon Major Business
Table 28. Biocon Targeted Drugs for NSCLC Product and Solutions
Table 29. Biocon Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Boehringer-Ingelheim Corporate Information, Head Office, and Major Competitors
Table 31. Boehringer-Ingelheim Major Business
Table 32. Boehringer-Ingelheim Targeted Drugs for NSCLC Product and Solutions
Table 33. Boehringer-Ingelheim Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Celgene Corporation Major Business
Table 36. Celgene Corporation Targeted Drugs for NSCLC Product and Solutions
Table 37. Celgene Corporation Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Drug International Limted Corporate Information, Head Office, and Major Competitors
Table 39. Drug International Limted Major Business
Table 40. Drug International Limted Targeted Drugs for NSCLC Product and Solutions
Table 41. Drug International Limted Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Fujifilm Kyowa Kirin Biologics Corporate Information, Head Office, and Major Competitors
Table 43. Fujifilm Kyowa Kirin Biologics Major Business
Table 44. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product and Solutions
Table 45. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Genvio Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 47. Genvio Pharma Limited Major Business
Table 48. Genvio Pharma Limited Targeted Drugs for NSCLC Product and Solutions
Table 49. Genvio Pharma Limited Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Hetero Drugs Corporate Information, Head Office, and Major Competitors
Table 51. Hetero Drugs Major Business
Table 52. Hetero Drugs Targeted Drugs for NSCLC Product and Solutions
Table 53. Hetero Drugs Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. ImClone Systems (Eli Lilly) Corporate Information, Head Office, and Major Competitors
Table 55. ImClone Systems (Eli Lilly) Major Business
Table 56. ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product and Solutions
Table 57. ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Incepta Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 59. Incepta Pharmaceuticals Major Business
Table 60. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions
Table 61. Incepta Pharmaceuticals Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Mylan Corporate Information, Head Office, and Major Competitors
Table 63. Mylan Major Business
Table 64. Mylan Targeted Drugs for NSCLC Product and Solutions
Table 65. Mylan Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Novartis Corporate Information, Head Office, and Major Competitors
Table 67. Novartis Major Business
Table 68. Novartis Targeted Drugs for NSCLC Product and Solutions
Table 69. Novartis Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Pfizer Corporate Information, Head Office, and Major Competitors
Table 71. Pfizer Major Business
Table 72. Pfizer Targeted Drugs for NSCLC Product and Solutions
Table 73. Pfizer Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Reliance Lifesciences Corporate Information, Head Office, and Major Competitors
Table 75. Reliance Lifesciences Major Business
Table 76. Reliance Lifesciences Targeted Drugs for NSCLC Product and Solutions
Table 77. Reliance Lifesciences Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Roche Corporate Information, Head Office, and Major Competitors
Table 79. Roche Major Business
Table 80. Roche Targeted Drugs for NSCLC Product and Solutions
Table 81. Roche Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 83. AstraZeneca Major Business
Table 84. AstraZeneca Targeted Drugs for NSCLC Product and Solutions
Table 85. AstraZeneca Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Cipla Corporate Information, Head Office, and Major Competitors
Table 87. Cipla Major Business
Table 88. Cipla Targeted Drugs for NSCLC Product and Solutions
Table 89. Cipla Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Teva Corporate Information, Head Office, and Major Competitors
Table 91. Teva Major Business
Table 92. Teva Targeted Drugs for NSCLC Product and Solutions
Table 93. Teva Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. OSI Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 95. OSI Pharmaceuticals Major Business
Table 96. OSI Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions
Table 97. OSI Pharmaceuticals Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 99. Glenmark Pharmaceuticals Major Business
Table 100. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions
Table 101. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 102. Natco Pharma Corporate Information, Head Office, and Major Competitors
Table 103. Natco Pharma Major Business
Table 104. Natco Pharma Targeted Drugs for NSCLC Product and Solutions
Table 105. Natco Pharma Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 106. Global Targeted Drugs for NSCLC Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 107. Global Targeted Drugs for NSCLC Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 108. Breakdown of Targeted Drugs for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 109. Targeted Drugs for NSCLC Players Head Office, Products and Services Provided
Table 110. Targeted Drugs for NSCLC Mergers & Acquisitions in the Past Five Years
Table 111. Targeted Drugs for NSCLC New Entrants and Expansion Plans
Table 112. Global Targeted Drugs for NSCLC Revenue (USD Million) by Type (2017-2022)
Table 113. Global Targeted Drugs for NSCLC Revenue Share by Type (2017-2022)
Table 114. Global Targeted Drugs for NSCLC Revenue Forecast by Type (2023-2028)
Table 115. Global Targeted Drugs for NSCLC Revenue by Application (2017-2022)
Table 116. Global Targeted Drugs for NSCLC Revenue Forecast by Application (2023-2028)
Table 117. North America Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 118. North America Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 119. North America Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 120. North America Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 121. North America Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 122. North America Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 123. Europe Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 124. Europe Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 125. Europe Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 126. Europe Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 127. Europe Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 128. Europe Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 129. Asia-Pacific Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 130. Asia-Pacific Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 131. Asia-Pacific Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 132. Asia-Pacific Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 133. Asia-Pacific Targeted Drugs for NSCLC Revenue by Region (2017-2022) & (USD Million)
Table 134. Asia-Pacific Targeted Drugs for NSCLC Revenue by Region (2023-2028) & (USD Million)
Table 135. South America Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 136. South America Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 137. South America Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 138. South America Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 139. South America Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 140. South America Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 141. Middle East & Africa Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 142. Middle East & Africa Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 143. Middle East & Africa Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 144. Middle East & Africa Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 145. Middle East & Africa Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 146. Middle East & Africa Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Targeted Drugs for NSCLC Picture
Figure 2. Global Targeted Drugs for NSCLC Revenue Market Share by Type in 2021
Figure 3. Target EGFR
Figure 4. Target ALK
Figure 5. Target HER2
Figure 6. Target ROS1
Figure 7. Target BRAF
Figure 8. Target MEK
Figure 9. Target VEGFR2
Figure 10. Target VEGF
Figure 11. Target MET
Figure 12. Targeted Drugs for NSCLC Revenue Market Share by Application in 2021
Figure 13. Squamous Cell Carcinoma of NSCLC Picture
Figure 14. Adenocarcinoma of NSCLC Picture
Figure 15. Large Cell Carcinoma of NSCLC Picture
Figure 16. Global Targeted Drugs for NSCLC Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 17. Global Targeted Drugs for NSCLC Revenue and Forecast (2017-2028) & (USD Million)
Figure 18. Global Targeted Drugs for NSCLC Revenue Market Share by Region (2017-2028)
Figure 19. Global Targeted Drugs for NSCLC Revenue Market Share by Region in 2021
Figure 20. North America Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Europe Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Asia-Pacific Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. South America Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 24. Middle East and Africa Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 25. Targeted Drugs for NSCLC Market Drivers
Figure 26. Targeted Drugs for NSCLC Market Restraints
Figure 27. Targeted Drugs for NSCLC Market Trends
Figure 28. Allergan Recent Developments and Future Plans
Figure 29. Amgen Recent Developments and Future Plans
Figure 30. ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans
Figure 31. Beacon Pharma Limited Recent Developments and Future Plans
Figure 32. BeiGene Recent Developments and Future Plans
Figure 33. Biocon Recent Developments and Future Plans
Figure 34. Boehringer-Ingelheim Recent Developments and Future Plans
Figure 35. Celgene Corporation Recent Developments and Future Plans
Figure 36. Drug International Limted Recent Developments and Future Plans
Figure 37. Fujifilm Kyowa Kirin Biologics Recent Developments and Future Plans
Figure 38. Genvio Pharma Limited Recent Developments and Future Plans
Figure 39. Hetero Drugs Recent Developments and Future Plans
Figure 40. ImClone Systems (Eli Lilly) Recent Developments and Future Plans
Figure 41. Incepta Pharmaceuticals Recent Developments and Future Plans
Figure 42. Mylan Recent Developments and Future Plans
Figure 43. Novartis Recent Developments and Future Plans
Figure 44. Pfizer Recent Developments and Future Plans
Figure 45. Reliance Lifesciences Recent Developments and Future Plans
Figure 46. Roche Recent Developments and Future Plans
Figure 47. AstraZeneca Recent Developments and Future Plans
Figure 48. Cipla Recent Developments and Future Plans
Figure 49. Teva Recent Developments and Future Plans
Figure 50. OSI Pharmaceuticals Recent Developments and Future Plans
Figure 51. Glenmark Pharmaceuticals Recent Developments and Future Plans
Figure 52. Natco Pharma Recent Developments and Future Plans
Figure 53. Global Targeted Drugs for NSCLC Revenue Share by Players in 2021
Figure 54. Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 55. Global Top 3 Players Targeted Drugs for NSCLC Revenue Market Share in 2021
Figure 56. Global Top 10 Players Targeted Drugs for NSCLC Revenue Market Share in 2021
Figure 57. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 58. Global Targeted Drugs for NSCLC Revenue Share by Type in 2021
Figure 59. Global Targeted Drugs for NSCLC Market Share Forecast by Type (2023-2028)
Figure 60. Global Targeted Drugs for NSCLC Revenue Share by Application in 2021
Figure 61. Global Targeted Drugs for NSCLC Market Share Forecast by Application (2023-2028)
Figure 62. North America Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)
Figure 63. North America Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)
Figure 64. North America Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)
Figure 65. United States Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Canada Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Mexico Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Europe Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)
Figure 69. Europe Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)
Figure 70. Europe Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)
Figure 71. Germany Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. France Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. United Kingdom Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Russia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Italy Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Asia-Pacific Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)
Figure 77. Asia-Pacific Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)
Figure 78. Asia-Pacific Targeted Drugs for NSCLC Revenue Market Share by Region (2017-2028)
Figure 79. China Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Japan Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. South Korea Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. India Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Southeast Asia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. Australia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. South America Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)
Figure 86. South America Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)
Figure 87. South America Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)
Figure 88. Brazil Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 89. Argentina Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 90. Middle East and Africa Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)
Figure 91. Middle East and Africa Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)
Figure 92. Middle East and Africa Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)
Figure 93. Turkey Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 94. Saudi Arabia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 95. UAE Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 96. Methodology
Figure 97. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
